Next Article in Journal
Protonated and Cationic Helium Clusters
Next Article in Special Issue
Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARγ Agonist via a Combined Computational and Functional Study
Previous Article in Journal
Filled Carbon Nanotubes as Anode Materials for Lithium-Ion Batteries
Previous Article in Special Issue
PPARα-Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 5
10.3390/molecules25051062
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?

by
Michele Tufano
and
Graziano Pinna
*
The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, 1601 W. Taylor Str., Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(5), 1062; https://doi.org/10.3390/molecules25051062
Submission received: 4 February 2020 / Revised: 20 February 2020 / Accepted: 21 February 2020 / Published: 27 February 2020
(This article belongs to the Special Issue Role of PPAR Receptors in Human Health and Disease)
Browse Figures
Versions Notes

Abstract

Recently, peroxisome proliferator-activated receptor (PPAR)-α and γ isoforms have been gaining consistent interest in neuropathology and treatment of neuropsychiatric disorders. Several studies have provided evidence that either the receptor expression or the levels of their endogenously-produced modulators are downregulated in several neurological and psychiatric disorders and in their respective animal models. Remarkably, administration of these endogenous or synthetic ligands improves mood and cognition, suggesting that PPARs may offer a significant pharmacological target to improve several neuropathologies. Furthermore, various neurological and psychiatric disorders reflect sustained levels of systemic inflammation. Hence, the strategy of targeting PPARs for their anti-inflammatory role to improve these disorders is attracting attention. Traditionally, classical antidepressants fail to be effective, specifically in patients with inflammation. Non-steroidal anti-inflammatory drugs exert potent antidepressant effects by acting along with PPARs, thereby strongly substantiating the involvement of these receptors in the mechanisms that lead to development of several neuropathologies. We reviewed running findings in support of a role for PPARs in the treatment of neurological diseases, including Alzheimer’s disease or psychiatric disorders, such as major depression. We discuss the opportunity of targeting PPARs as a future pharmacological approach to decrease neuropsychiatric symptoms at the same time that PPAR ligands resolve neuroinflammatory processes.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are non-steroid nuclear receptors, which dimerize with the retinoid X receptor (RXR) and bind to PPAR-responsive regulatory elements (PPRE) in the promoter region of target genes (Figure 1) [1]. PPARs are expressed in many cellular types and tissues and exhibit differences in ligand specificity and activation of metabolic pathways [2]. In humans, among all known transcriptional factors belonging to the nuclear receptor superfamily, three isoforms of PPARs have been characterized: PPAR-α, PPAR-β/δ, and PPAR-γ, also known as NR1C1, NR1C2, and NR1C3, respectively [3]. PPARs are a target for fatty acids (unsaturated, mono-unsaturated, and poly-unsaturated), for which they mediate binding and transport, as well as oligosaccharides, polyphenols, and numerous synthetic ligands [4]. Furthermore, they are involved in a series of molecular processes, ranging from peroxisomal regulation and mitochondrial β-oxidation to thermogenesis and lipoprotein metabolism [5]. PPAR distribution changes in different organs and tissues. In rodent central nervous system, the three isoforms are widely co-expressed across brain areas and in circuitry that are responsible for mediating stress-responses, which supports a role in several neuropsychopathologies by mediating anti-inflammatory and metabolic actions [6,7]. Intriguingly, both synthetic and endogenously-produced PPAR agonists have shown benefits for treatment of mood disorders and neurological diseases [8].
By enhancing free fatty acid uptake, PPARs may improve insulin sensitivity and beta-cell properties in hyperglycemia in patients affected with type 2 diabetes [14]. For example, thiazolidinediones, including pioglitazone and rosiglitazone, are synthetic ligands that selectively bind at PPAR-γ and are used clinically for the treatment of diabetes [15]. However, given their side effects on weight gain, congestive heart failure, bone fractures, and macular and peripheral edema, the Food and Drug Administration (FDA) has limited their use [16]. PPAR-α synthetic ligands, including the fibrates (fenofibrate, clofibrate) (depicted in Figure 2) are characterized by a much safer pharmacological profile and are widely prescribed to lower high cholesterol blood levels and triglycerides [17]. While PPAR-α and γ endogenous and synthetic ligands have been well characterized for the treatment of diabetes and cardiovascular disease, their central neuronal effects on behavior and neuropathology have only emerged recently [7].
The efficacy of PPAR-γ agonists on behavior was initially shown in rodent models of anxiety and depression, where the administration of rosiglitazone significantly reduced the immobility time in the forced swim test [18]. This antidepressant effect was also observed in clinical trials where administration of pioglitazone or rosiglitazone improved symptoms in patients with major depression [16]. Importantly, the improvement in depression correlated with normalization of inflammatory biomarkers (e.g., IL-6) and insulin resistance, suggesting an intriguing link among PPAR-γ-activation, depression, inflammation, and metabolism [16].
These findings highlight the potential therapeutic value of PPAR-γ agonists in the treatment of neuropsychiatric disorders [16,18,19]. Furthermore, they encourage developing new antidepressant drugs beyond the traditional selective serotonin reuptake inhibitors (SSRIs). SSRIs are relatively inefficient because they only improve symptoms in about half of patients with mood disorders, including major depression and post-traumatic stress disorder (PTSD) [9]. Hence, there is an urgent need for developing new treatment strategies and identifying novel neurobiological targets and biomarkers that may stimulate discovery of novel ligands [9].
Recently, neuroinflammation has been the focus of new scientific evidence that is convincingly demonstrating its contribution to neuropathophysiology of mood disorders [20]. Several studies have recently observed elevated peripheral and central neuroinflammatory markers in psychiatric disorders, such as PTSD, suicidal behavior, and schizophrenia [21,22,23]. It is remarkable that patients with high levels of neuroinflammation respond poorly to classical antidepressants, suggesting that targeting neuroinflammatory pathways may offer a therapeutic strategy to revert or alleviate mood symptoms as well [24]. Intriguingly, dietary interventions have been tested in several neuropsychiatric disorders, such as multiple sclerosis (MS), anxiety, and depression [25,26]. As molecular targets for various natural ligands found in a number of aliments, PPARs may shed light into the molecular mechanisms underlying the success of dietary treatments in nutritional psychiatry [27].
Herein, we review recent findings on the emerging role of PPAR-α and PPAR-γ in the treatment of neuropsychiatric disorders with a particular focus on their role in the regulation of inflammation.

2. Brain Distribution of PPARs in the Rodent Brain

The distribution of PPARs changes over different tissues. In rat brain, the three isoforms are co-expressed during neurodevelopment. Later in life, PPAR-β/δ becomes the most predominant isoform and subsequently there is a decrease in the expression of PPAR-α and PPAR-γ [28]. However, PPAR-α is widely expressed in amygdala, prefrontal cortex, thalamic nuclei, nucleus accumbens, ventral tegmental area, and basal ganglia [29,30]. In these regions, PPAR-α expression is found at the highest levels in neurons, followed by astrocytes, where it was detected in cell body and astrocytic processes, and is weakly expressed in microglia. PPAR-α is the only isotype that colocalizes with all cell types and it is the most expressed isotype in astrocytes [30]. PPAR-β/δ has a ubiquitous distribution across the brain. It is the most widely expressed isotype both in the brain and the periphery, and studies suggest a regulatory role for PPAR-β/δ on the other isoforms [31]. PPAR-γ is highly expressed in the amygdala, piriform cortex, dental gyrus and basal ganglia, with lower levels in thalamic nuclei and hippocampal formation [6,30]. PPAR-γ is also more widely expressed in neurons than astrocytes where it varies across brain regions, with higher expression in nucleus accumbens followed by the prefrontal cortex. Interestingly, PPAR-γ is not expressed in microglia of mouse or human brain unless there is a condition of a microglial functional state, as it appears after lipopolysaccharide (LPS) treatment [30]. While PPAR-β/δ is not found in microglia, PPAR-α is the only isotype expressed under normal and LPS conditions [30]. PPAR expression across brain areas in circuitry that regulates stress-response suggests that they may play a role in several neuropsychopathologies by mediating anti-inflammatory and metabolic actions. Intriguingly, both synthetic and endogenously-produced PPAR agonists have shown benefits for treatment of mood disorders and neurological diseases [7,8,10,32,33].

3. Neuropsychiatric Disorders and PPARs

3.1. Mood Disorders

Major depressive disorder (MDD) affects 15%–20% of the general American population, thereby representing a remarkable burden for society, exacerbated by its chronicity and comorbidity with other prevalent mood disorders, such as PTSD and suicide, and drug use disorder [34,35]. It is the second most common cause of disability worldwide and it is expected to become the main cause in high-income countries by 2030 [36]. Currently, FDA-approved treatments for depression include the SSRI antidepressants and the serotonin-norepinephrine reuptake inhibitor (SNRIs), which have a high rate of non-responders [37]. Additionally, these medications might take up to several weeks to induce pharmacological effects and patients often drop-off treatment because of a variety of unwanted secondary effects, which comprise insomnia, headache, sexual dysfunction, and dry mouth [38]. While novel therapeutic strategies are urgently needed for the management of MDD, PTSD, and other mood disorders, the nuclear receptors PPAR-α and γ are gaining consistent interest as new promising targets for treating behavioral dysfunction (please see Table 1 and Table 2 for a summary) [39]. This is further substantiated by the recent discovery that stimulation of PPAR-α can enhance neurosteroid biosynthesis [10], which is implicated in the etiopathology of mood disorders and their treatment [7,40,41,42,43].

3.1.1. PPAR-α

PPAR-α selective agonists (Figure 2) have been associated with antidepressant effects in murine models of stress-induced depression [44,73]. The PPAR-α agonist WY14643 improved depressive-like behavior in the chronic social defeat stress model, in the tail suspension test, and in forced swim test, commonly used rodent paradigms to evaluate depression-like behavior [74]. The anti-depressant activity of WY14643 appeared to involve activation of the brain derived neurotropic factor (BDNF) signaling cascade [44], a pathway implicated in a range of neuronal processes (depicted in Figure 1) [75,76,77,78]. It is well known that BDNF levels are found to be decreased in the hippocampus of depressed individuals and in animal models of this disorder [79,80,81,82]. Furthermore, the action of antidepressants, like fluoxetine, increase BDNF levels, which in turn correlates with an improvement of behavioral dysfunction [83]. Fenofibrate, another selective synthetic agonist of PPAR-α (depicted in Figure 2), is a fibric acid derivative largely prescribed in the treatment of primary hypercholesterolemia [84]. Similar to WY14643, fenofibrate administration in a rodent model of depression exerts antidepressant-like effects via activation of PPAR-α-mediated promotion of hippocampal BDNF signaling cascade [45]. Fenofibrate also improved anxiety-like behavior in an animal model of PTSD [10].
PPAR-α is also involved in hippocampal long-term memory processes by upregulating plasticity-related genes [85]. Intriguingly, PPAR-α is widely expressed in hippocampal neurons, where it controls the calcium influx through transcriptional regulation of cyclic AMP response element binding (CREB) [86,87]. The PPAR-mediated transcriptional regulation of CREB also stimulates BDNF expression, which improves learning and memory in animal models of Alzheimer’s disease [88]. Interestingly, the HMG-CoA reductase inhibitor, simvastatin, which is used to decrease triglycerides levels and reduce the risk of heart disease, is also able to reverse the depression-like behaviors induced in rats by chronic mild stress (CMS) [46]. This action also appears to be mediated by enhancing the hippocampal expression of BDNF signaling pathway via the PPAR-α-mediated activation of CREB [88]. Consistent with these findings, in a chronic stress-induced mouse model of depression, PPAR-α expression is decreased in the hippocampus, which in turn results in reduced hippocampal BDNF expression [89]. Conversely, genetic overexpression of PPAR-α induces antidepressant effects by a CREB-mediated biosynthesis of BDNF. Both genetic or pharmacological inhibition of PPAR-α blocks the anti-depressive effects of fluoxetine, thereby suggesting its involvement in the molecular mechanisms of antidepressant drug action [89].
Downregulation of PPAR-α expression was recently associated with the molecular mechanisms underlying behavioral deficits [10]. Likewise, its anti-depressive pharmacological effects correlated with the stimulation of neurosteroid biosynthesis [10]. The main PPAR-α endogenous agonist, N-palmitoylethanolamine (PEA) is an anti-inflammatory, analgesic, and anti-allergic compound clinically tested for its neuroprotective effects in multiple sclerosis (MS), Alzheimer’s disease (AD), and Parkinson’s disease (PD) [90,91]. PEA can be produced endogenously or acquired through plant-based food sources and it is endogenously metabolized by the fatty acid amide hydrolase (FAAH) [91], which is an enzyme involved in the metabolism of endocannabinoids, including anandamide (AEA) [92]. As an endogenous ligand, PEA activates the G-protein coupled receptor, GPR55, while showing low affinity for the cannabinoid receptor type-1 (CB1) and type2 (CB2) [93]. However, its therapeutic behavioral effects appear to be mediated via PPAR-α binding and activation [10,94]. PEA administration in socially isolated mice, a model of protracted stress-induced PTSD [48,49], normalized reduced brain levels of allopregnanolone, a GABAergic neurosteroid, which is found decreased in patients with depression and PTSD [95,96,97,98,99]. In the socially isolated mouse, PEA improved contextual fear responses and facilitated contextual fear extinction and fear extinction retention, as well as ameliorated depressive-like and anxiety-like behavior by increasing corticolimbic levels of allopregnanolone [10]. Consistently, in a cohort of Ugandan war survivors affected by PTSD, the hair levels of PEA, oleoylethanolamide (OEA), and stearoylethanolamide (SEA) were found to be decreased when compared with levels of war survivors without current or lifetime PTSD [100], thus suggesting a decreased PPAR-α signal pathway in PTSD. While it is important that these findings will be confirmed also in blood and post-mortem brain of PTSD patients [101], this observation provides support to the involvement of the PPAR-allopregnanolone axis dysfunction in PTSD. Together with the findings that allopregnanolone has been found decreased in cerebrospinal fluid (CSF) and plasma of both male and female PTSD and MDD patients [95,97,98,99,102], these clinical data provide a translational example with PTSD animal models [103].

3.1.2. PPAR-γ

In 2009, a case report showed that pioglitazone improved symptoms in a 55-year-old woman affected by unipolar major depression [104]. In another study, pioglitazone (Figure 2) was administered in a 24-week double-blind randomized clinical trial in 145 patients with a metabolic syndrome [65]. Patients showed improvement in anxiety and depression symptoms following pioglitazone treatment. Furthermore, pioglitazone showed anxiolytic effects in nondiabetic insulin-resistant patients [65]. In a double-blind placebo-controlled clinical trial with patients not showing any metabolic syndrome or diabetes, pioglitazone was beneficial in the treatment of MDD [105]. Administration with pioglitazone (15–30 mg/day) given for 8 weeks to a cohort of 34 patients with bipolar depression also improved depressive symptoms [66]. However, when tested for efficacy in a 8-week, double-blind, randomized, placebo-controlled trial of 37 patients, pioglitazone (15–45 mg/day) failed to improve bipolar depression symptoms [67].
In preclinical studies, administration with pioglitazone improved depression-like behavior induced by LPS [12]. After pioglitazone administration, the NF-κB/IL-6/STAT3 pathway was inhibited with concomitant down-regulation of the CREB/BDNF pathway [12,13]. In a mouse model of depression, the pharmacological effects of pioglitazone in improving behavioral deficits involved central serotonergic neurotransmission [12]. In mice exposed to CMS, administration of pioglitazone (2.5 mg/kg) decreased the CMS-induced microglial activated status (Iba1 +) in the hippocampus and improved the microglial neuroprotective phenotype, resulting in an overall amelioration of depressive-like behavior [47]. Interestingly, this behavioral improvement was associated with the inhibition of microglia-mediated neuroinflammation [47]. Indeed, after pioglitazone treatment, the expression of pro-inflammatory molecules (IL-1β, IL-6, and TNFα) was reduced and the levels of anti-inflammatory cytokines (IL-4, IL-10, and TGF-β) were increased in CMS mice [47]. Moreover, decreased PPAR-γ mRNA and protein expression in adipose tissue were correlated with chronic social defeat stress. Rosiglitazone also elicited antidepressant and anxiolytic-like effects through the PPAR-γ-mediated decrease in adiponectin production, suggesting that the PPAR-γ-adiponectin axis may be involved both in metabolism and stress-related homeostasis [106].

3.2. Neurodevelopmental Disorders

The involvement of PPARs in psychiatric disorders is not limited to MDD and PTSD. Schizophrenia has been associated with increased inflammation, suggesting that the neuroinflammatory processes may play a role in the pathophysiology of this prevalent mental disorder [107]. In peripheral blood mononuclear cells (PBMC) extracted from chronic schizophrenic patients, a decreased expression and activity of PPAR-γ correlated with lower plasma levels of its endogenous ligand, 15d-prostaglandin J2, which overall indicates a state of increased inflammation [108]. Another study in patients affected by schizophrenia investigated the expression of inflammatory and metabolic genes [109]. Expression of PPAR-γ was increased while PPAR-α was decreased, suggesting a metabolic-inflammatory imbalance in schizophrenia [109]. Pioglitazone provided benefits in reversing this metabolic condition. Also, administration of pioglitazone to the GluN1 knockdown model of schizophrenia improved long-term memory and helped to restore cognitive endophenotypes [50]. Unlike most anti-psychotics, pioglitazone had a restorative effect on cognitive function (measured by the puzzle box assay), thus suggesting a potential impact of pioglitazone as an augmentation therapy in schizophrenia [50,110].
Additionally, for its anti-inflammatory and neuroprotective properties [111], PPAR-α activation by fenofibrate prevented prenatal maternal immune activation, which in a rat model is associated with the risk of developing schizophrenia in the offspring [112]. Remarkably, prenatal administration of pioglitazone dampens the schizophrenia-like behavior observed in male offspring after prenatal maternal immune activation [112].
Autism spectrum disorder (ASD) is also characterized by neuroinflammation, oxidative stress and depletion of glutathione in the brain [113]. In clinical studies, pioglitazone was tested in a 16-week prospective cohort of 25 autistic children, showing good tolerability and leading to a statistically significant improvement in repetitive behaviors, social withdrawal, and externalizing behaviors [70]. However, randomized controlled trials are still needed in order to fully validate pioglitazone as valuable treatment for ASD [70].
In preclinical studies, administering pioglitazone decreases inflammation and oxidative stress, thus reverting the ASD-like behavior [114]. The ASD-like behavioral deficits can be induced in rats with a postnatal treatment with propionic acid, which increases inflammation and oxidative stress [51]. Treatment with pioglitazone from postnatal day 24, mitigated the ASD-like behavior and reduced oxidative stress and inflammation by reducing IL-6 and TNF-α while increasing IL-10 in cerebellum, prefrontal cortex and brainstem [115]. A natural ligand of PPAR-γ is resveratrol, which is also able to prevent social behavioral impairments in a rodent ASD model [116,117].
Consistent with a PPAR-α activation, neurobehavioral and biochemical benefits in an ASD animal model were observed following administration with fenofibrate that resulted in reduced oxidative stress and inflammation in several brain regions [52]. PPAR-α is required for normal cerebral functions and its genetic ablation leads to repetitive behaviors and cognitive inflexibility in mice [118]. In another rodent model of ASD, the BTBR T + tf/J (BTBR) mouse, PEA reverted the altered phenotype and improved ASD-like behavior through a PPAR-α activation. This effect was accompanied by decreased levels of inflammatory cytokines in serum, hippocampus, and colon [53]. PEA administration restored the hippocampal BDNF signaling pathway in BTBR mice and improved mitochondrial dysfunction, which has been observed in ASD (Table 1 and Table 2) [53].
PPAR-β/δ has also an effect in improving inflammation related to ASD [119]. Treatment with the selective agonist, GW0742, improved repetitive behaviors and lowered thermal sensitivity responses in the BTBR rodents, while decreasing pro-inflammatory and increasing anti-inflammatory cytokines [54].
These findings strongly support the involvement of PPARs in the neuropathology of mood and neurodevelopmental disorders [100]. A PPAR-α-allopregnanolone (i.e., endocannabinoid-like/neurosteroids) cross-talk may have an impact for establishing relevant novel targets for the treatment of PTSD and major depression [9]. Intriguingly, these newly observed link between the endocannabinoid-like system and biosynthesis of neurosteroids may additionally provide bio-signatures for the diagnosis and treatment of psychiatric disorders, which still rely on subjective measures based on the DSM-5 criteria [120]. Furthermore, PPAR-γ agonists, including pioglitazone, have shown promising antidepressant effects in several clinical trials [16,65,66,67]. It is also remarkable that non-steroidal anti-inflammatory drugs, including ibuprofen and aspirin, whose mechanism of action includes a PPAR-γ activation, have consistently shown potent antidepressant effects [121].
Collectively, these studies involving PPAR-α and γ in the neuropathophysiology of psychiatric disorders have opened up new opportunities for the development of new therapeutics, which represent a novel emerging field of neuropsychopharmacology [18,66,89,122].

3.3. Neurological Disorders

In Alzheimer’s disease (AD) the deposition of amyloid β triggers neuroinflammation and oxidative damage [122,123]. However, the pathogenic mechanisms for AD onset and progression are far from being elucidated. For their involvement in neuroinflammation, oxidative stress and energy metabolism, PPARs have been considered as promising therapeutic target for AD (please see Table 1 and Table 2) [123,124]. PPAR-γ signaling is coordinated with the Wnt/beta-catenin signaling in opposite ways. Wnt/beta-catenin is downregulated when PPAR-γ is upregulated in AD [125]. Imbalance in the Wnt/beta-catenin/PPAR-γ regulation plays a role in physiopathology of neurological disorders owing to its involvement in oxidative stress and cell death through regulation of metabolic enzymes [125]. Administration of pioglitazone in a genetically modified AD mouse model showed reductions in both soluble and insoluble amyloid β, while improving memory, learning deficits, and preventing neurodegeneration [126]. However, in clinical studies, pioglitazone showed no significant effects on cognitive outcomes [62,71].
To remediate the effects of neurodegeneration, the agonists L165, 041, and F-L-Leu, acting on PPAR-β/δ and PPAR-γ, respectively, have been simultaneously administered in a Streptozotocin rat model of AD [63]. The treatment improved myelin and neuronal maturation, mitochondrial proliferation, and function, while decreasing neuroinflammation, indicating a role, not only for PPAR-γ, but also for PPAR-β/δ in the pathology of AD [63]. On the other hand, activation of PPAR-α by PEA has proven efficacy in inhibiting amylogenesis, neuroinflammation, neurodegeneration and Tau hyperphosphorylation [124]. Whether PEA could play a role alone or adjuvant of other AD therapeutics should be further investigated [127]. The Aβ-induced tau protein hyperphosphorylation is also reduced by cannabidiol (CBD) administration, through the PPAR-γ and Wtn/β-catenin stimulation, which underscores a role for this phytocannabinoid in reducing neuroinflammation and oxidative stress [128].
Analogously, owing to their engagement in the regulation of neuroinflammation and innate immune response, PPAR dysfunction may play a role in the molecular mechanisms that trigger multiple sclerosis (MS) [129,130]. Interestingly, in PBMC of patients affected by MS, PPAR-γ expression was decreased [131, 132]. Troglitazone (a PPAR-γ agonist) administration attenuated inflammation and ameliorated experimental autoimmune encephalomyelitis (EAE), an animal model of MS [64]. Moreover, a polymorphism (Pro12A) on the PPAR-γ gene is correlated with higher risk of delayed MS onset [133]. When tested for efficacy in a cohort of 24 patients, pioglitazone showed no improvement in clinical symptoms after 1 year of treatment, although a decrease in grey matter atrophy and reduced lesion burden was observed using magnetic resonance imaging (MRI) [72].
Parkinson’s disease (PD) symptoms have been reproduced in rodent models by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP), which induces degeneration of dopaminergic neurons in the substantia nigra [134]. When administered in this model, pioglitazone protects against MPTP-induced neurotoxicity, decreasing microglial activation, and iNOS-positive cells, as well as inhibiting monoamine oxidase-B expression. In a chronic model of MPTP, rosiglitazone administration protected from loss of dopaminergic neurons and prevented olfactory and motor alteration [55,56,57]. MHY908, a PPAR-α/γ dual agonist, exerts neuroprotective effects by reducing microglial activation and neuroinflammation, thereby diminishing dopaminergic neuronal damage in a MPTP mouse model of PD [135]. Similarly, the PPAR-γ agonist, MDG548 mediates neuroprotection in LPS-stimulated microglia and, in the MPTP mouse model, by boosting phagocytosis and anti-inflammatory cytokines production (e.g., IL-10) [136]. This further supports PPAR-γ engagement in microglial function, phagocytosis and neuroinflammation. The overexpression of PPAR-γ coactivator-1α (PGC-1α), a master regulator of mitochondrial metabolism and oxidative stress [137], protects MPTP-induced dopaminergic neuronal degeneration. Interestingly, resveratrol-mediated PGC-1α activation also protected against dopaminergic neuronal degeneration in the MPTP mouse model, with efficiency comparable to the PGC-1α overexpression [138]. This finding suggests that resveratrol and other compounds, which act on PPAR-γ and PGC-1α might be beneficial as therapeutic agents in PD pathophysiology and possibly in other neurological disorders [138].
PPARs have also shown beneficial effects in improving epilepsy, a chronic disorder characterized by unprovoked seizures, which affects 1% of the human population [139]. Administration of a long-term fenofibrate diet negatively modulated the nicotine-induced increase of large inhibitory postsynaptic currents recorded in pyramidal neurons and improved motor-behavioral seizures [140]. Therefore, PPAR-α has been proposed as a therapeutic target for nocturnal frontal lobe epilepsy, which is a form of idiopathic epilepsy with an autosomal inherited component [140]. PPAR-α also plays a role in the duration and occurrence of seizures (measured by a spike-wave discharges on EEG recordings) in WAG/Rij rats, one of the most used models of human absence epilepsy [141], where PEA attenuates seizures by binding PPAR-α and indirectly by activating the CB1 receptor [61].
Altogether, the results obtained from testing PPAR-α and γ agonists (such as fenofibrate, pioglitazone, resveratrol and rosiglitazone) in various neurological disorders support PPAR-α and PPAR-γ as potential novel targets for the therapeutic management of prevalent and debilitating conditions, such as Alzheimer’s and Parkinson’s disease. Undoubtedly, more clinical trials are required to demonstrate the efficacy and safety of PPAR agonists and, considering the side effects linked to treatment with some PPAR-γ agonists, it would be necessary to explore alternative strategies for administration, as well as adjusting for doses and delivery of drugs. Further understanding of the molecular mechanism of PPAR’s role in neuroinflammation, which is emerging as a common process in neuropsychiatric disorders, as well as, a better comprehension of their activation by endogenous ligands, which can also be introduced by food sources, is also needed.

4. Conclusions

PPARs are implicated in a variety of molecular processes that bridge metabolism to inflammation, where they have been extensively studied. PPAR-α and PPAR-γ synthetic ligands (e.g., fenofibrate, rosiglitazone) have been approved by the FDA for treatment of high cholesterol levels and diabetes, respectively. Remarkably, their role in the regulation of behavioral dysfunction is just emerging and their engagement in the pathophysiology and treatment of psychiatric and neurological disorders is becoming an intriguing new treatment opportunity to manage these conditions. In this respect, PPAR’s involvement in neuroinflammatory processes associated with psychiatric and neurological disorders is relevant not only for discovering novel therapeutics that activate PPARs, but also for exploring new biomarker candidates that may help with the prevention and diagnosis of these debilitating conditions [9,33]. Furthermore, the finding that endogenous ligands, including PEA or other natural ligands are found in aliments, opens the field of nutritional psychiatry to investigate micronutrients that activate PPARs [142]. This trend may lead to developing natural therapeutic approaches for treating neuropsychiatric disorders through functional foods.

5. Patents

Graziano Pinna has a patent pending application on PEA and PPAR-α agonists in the treatment of neuropsychiatric disorders.

Acknowledgments

This study was supported by the United States Department of Defense Grant W81XWH-15-10521 to Graziano Pinna.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Chawla, A. Nuclear Receptors and Lipid Physiology: Opening the X-Files. Science 2001, 294, 1866–1870. [Google Scholar] [CrossRef]
  2. Iglesias, J.; Morales, L.; Barreto, G.E. Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs. Mol. Neurobiol. 2016, 54, 2518–2538. [Google Scholar] [CrossRef]
  3. Corrales, P.; Vidal-Puig, A.; Medina-Gomez, G. PPARs and Metabolic Disorders Associated with Challenged Adipose Tissue Plasticity. Int. J. Mol. Sci. 2018, 19, 2124. [Google Scholar] [CrossRef]
  4. Grygiel-Górniak, B. Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications - a review. Nutr. J. 2014, 13, 17. [Google Scholar] [CrossRef]
  5. Tyagi, S.; Gupta, P.; Saini, A.S.; Kaushal, C.; Sharma, P. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J. Adv. Pharm. Technol. 2011, 2, 236–240. [Google Scholar] [CrossRef] [PubMed]
  6. Moreno, S.; Vecchioli, S.F.; Cerù, M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neurosci. 2004, 123, 131–145. [Google Scholar] [CrossRef] [PubMed]
  7. Nisbett, K.E.; Pinna, G. Emerging therapeutic role of PPAR–α in cognition and emotions. Front. Pharmacol. 2018, 9, 998. [Google Scholar] [CrossRef] [PubMed]
  8. Rolland, B.; Deguil, J.; Jardri, R.; Cottencin, O.; Thomas, P.; Bordet, R. Therapeutic prospects of PPARs in psychiatric disorders: A comprehensive review. Curr. Drug Targets 2013, 14, 724–732. [Google Scholar] [CrossRef] [PubMed]
  9. Locci, A.; Pinna, G. Neurosteroid biosynthesis down-regulation and changes in GABAA receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. Br. J. Pharmacol. 2017, 174, 3226–3241. [Google Scholar] [CrossRef] [PubMed]
  10. Locci, A.; Pinna, G. Stimulation of peroxisome proliferator-activated receptor-α by N- palmitoylethanolamine engages allopregnanolone biosynthesis to modulate emotional behavior. Biol. Psychiatry 2019, 85, 1036–1045. [Google Scholar] [CrossRef]
  11. Balan, I.; Beattie, M.C.; O’Buckley, T.K.; Aurelian, L.; Morrow, A.L. Endogenous neurosteroid (3α,5α)3-hydroxypregnan-20-one inhibits toll-like-4 receptor activation and pro-inflammatory signaling in macrophages and brain. Sci. Rep. 2019, 9, 1220. [Google Scholar] [CrossRef] [PubMed]
  12. Liao, L.; Zhang, X.; Li, J.; Zhang, Z.; Yang, C.; Rao, C.; Zhou, C.; Zeng, L.; Zhao, L.; Fang, L.; et al. Pioglitazone attenuates lipopolysaccharide-induced depression-like behaviors, modulates NF-κB/IL-6/STAT3, CREB/BDNF pathways and central serotonergic neurotransmission in mice. Int. Immunopharmacol. 2017, 49, 178–186. [Google Scholar] [CrossRef] [PubMed]
  13. Xu, D.; Lian, D.; Wu, J.; Liu, Y.; Zhu, M.; Sun, J.; He, D.; Li, L. Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis. J. Neuroinflammation 2017, 14, 156. [Google Scholar] [CrossRef] [PubMed]
  14. Lincoff, A.M.; Tardif, J.-C.; Schwartz, G.G.; Nicholls, S.; Rydén, L.; Neal, B.; Malmberg, K.; Wedel, H.; Buse, J.B.; Henry, R.R.; et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus. JAMA 2014, 311, 1515–1525. [Google Scholar] [CrossRef] [PubMed]
  15. Satirapoj, B.; Watanakijthavonkul, K.; Supasyndh, O. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial. PLoS ONE 2018, 13, e0206722. [Google Scholar] [CrossRef] [PubMed]
  16. Colle, R.; De Larminat, D.; Rotenberg, S.; Hozer, F.; Hardy, P.; Verstuyft, C.; Feve, B.; Corruble, E. PPAR-? Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry 2016, 50, 49–55. [Google Scholar] [CrossRef]
  17. Ferri, N.; Corsini, A.; Sirtori, C.; Ruscica, M. PPAR-α agonists are still on the rise: An update on clinical and experimental findings. Expert Opin. Investig. Drugs 2017, 26, 593–602. [Google Scholar] [CrossRef]
  18. Da Rosa, A.; Kaster, M.; Binfaré, R.W.; Morales, S.; Martin-Aparicio, E.; Navarro-Rico, M.L.; Martínez, A.; Medina, M.; Garcia, A.G.; Lopez, M.G.; et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuro-Psychopharmacology Biol. Psychiatry 2008, 32, 1549–1556. [Google Scholar] [CrossRef]
  19. Ahmed, A.A.E.; Al-Rasheed, N.M.; Al-Rasheed, N.M. Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. Behav. Pharmacol. 2009, 20, 635–642. [Google Scholar] [CrossRef]
  20. Bhattacharya, A.; Derecki, N.C.; Lovenberg, T.W.; Drevets, W.C. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacol. 2016, 233, 1623–1636. [Google Scholar] [CrossRef]
  21. Passos, I.C.; Vasconcelos-Moreno, M.P.; Costa, L.G.; Kunz, M.; Brietzke, E.; Quevedo, J.; Salum, G.; Magalhães, P.V.; Kapczinski, F.; Kauer-Sant’Anna, M. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2015, 2, 1002–1012. [Google Scholar] [CrossRef]
  22. Tomasik, J.; Rahmoune, H.; Guest, P.; Bahn, S. Neuroimmune biomarkers in schizophrenia. Schizophr. Res. 2016, 176, 3–13. [Google Scholar] [CrossRef] [PubMed]
  23. Coryell, W.; Wilcox, H.C.; Evans, S.J.; Pandey, G.N.; Jones-Brando, L.; Dickerson, F.; Yolken, R. Aggression, impulsivity and inflammatory markers as risk factors for suicidal behavior. J. Psychiatr. Res. 2018, 106, 38–42. [Google Scholar] [CrossRef]
  24. Adzic, M.; Brkic, Z.; Mitic, M.; Francija, E.; Jovicic, M.J.; Radulovic, J.; Maric, N.P. Therapeutic Strategies for Treatment of Inflammation-related Depression. Curr. Neuropharmacol. 2018, 16, 176–209. [Google Scholar] [CrossRef] [PubMed]
  25. Altowaijri, G.; Fryman, A.; Yadav, V. Dietary Interventions and Multiple Sclerosis. Curr. Neurol. Neurosci. Rep. 2017, 17, 28. [Google Scholar] [CrossRef] [PubMed]
  26. Opie, R.S.; O’Neil, A.; Itsiopoulos, C.; Jacka, F.N. The impact of whole-of-diet interventions on depression and anxiety: a systematic review of randomised controlled trials. Public Heal. Nutr. 2015, 18, 2074–2093. [Google Scholar] [CrossRef] [PubMed]
  27. Goto, T. A review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors. Biosci. Biotechnol. Biochem. 2018, 83, 579–588. [Google Scholar] [CrossRef]
  28. Braissant, O.L.I.V.I.E.R.; Foufelle, F.; Scotto, C.H.R.I.S.T.I.A.N.; Dauça, M.I.C.H.E.L.; Wahli, W.A.L.T.E.R. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137, 354–366. [Google Scholar] [CrossRef]
  29. Dickey, A.S.; Pineda, V.V.; Tsunemi, T.; Liu, P.P.; Miranda, H.C.; Gilmore-Hall, S.K.; Lomas, N.; Sampat, K.R.; Buttgereit, A.; Torres, M.-J.M.; et al. PPAR-δ is repressed in Huntington’s disease, is required for normal neuronal function and can be targeted therapeutically. Nat. Med. 2015, 22, 37–45. [Google Scholar] [CrossRef]
  30. Warden, A.; Truitt, J.; Merriman, M.; Ponomareva, O.; Jameson, K.; Ferguson, L.B.; Mayfield, R.D.; Harris, R.A. Localization of PPAR isotypes in the adult mouse and human brain. Sci. Rep. 2016, 6, 27618. [Google Scholar] [CrossRef]
  31. Aleshin, S.; Strokin, M.; Sergeeva, M.; Reiser, G. nexus of PPAR a - and PPAR c -dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses. Neurochem. Int. 2013, 63, 322–330. [Google Scholar] [CrossRef] [PubMed]
  32. Scheggi, S.; Melis, M.; De Felice, M.; Aroni, S.; Muntoni, A.L.; Pelliccia, T.; Gambarana, C.; De Montis, M.G.; Pistis, M. PPARα modulation of mesolimbic dopamine transmission rescues depression-related behaviors. Neuropharmacology 2016, 110, 251–259. [Google Scholar] [CrossRef] [PubMed]
  33. Locci, A.; Pinna, G. Social isolation as a promising animal model of PTSD comorbid suicide: Neurosteroids and cannabinoids as possible treatment options. Prog. Neuro-Psychopharmacology Biol. Psychiatry 2019, 92, 243–259. [Google Scholar] [CrossRef] [PubMed]
  34. Krishnan, V.; Nestler, E.J. The molecular neurobiology of depression. Nature. 2008, 455, 894–902. [Google Scholar] [CrossRef] [PubMed]
  35. Dean, J.; Keshavan, M. The neurobiology of depression: An integrated view. Asian J. Psychiatry 2017, 27, 101–111. [Google Scholar] [CrossRef] [PubMed]
  36. Mathers, C.D.; Loncar, D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med. 2006, 3, e442. [Google Scholar] [CrossRef] [PubMed]
  37. Tundo, A.; De Filippis, R.; Proietti, L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J. Psychiatry 2015, 5, 330–341. [Google Scholar] [CrossRef]
  38. Albert, P.; Benkelfat, C.; Descarries, L. The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos. Trans. R. Soc. B: Biol. Sci. 2012, 367, 2378–2381. [Google Scholar] [CrossRef]
  39. Henter, I.; De Sousa, R.T.; Gold, P.W.; Brunoni, A.R.; Zarate, C.A.; Machado-Vieira, R. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. Expert Rev. Clin. Pharmacol. 2017, 10, 153–166. [Google Scholar] [CrossRef]
  40. Pinna, G.; Rasmusson, A.M. Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder. J. Neuroendocr. 2012, 24, 102–116. [Google Scholar] [CrossRef]
  41. Pinna, G.; Costa, E.; Guidotti, A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacol. 2006, 186, 362–372. [Google Scholar] [CrossRef] [PubMed]
  42. Raber, J.; Arzy, S.; Bertolus, J.B.; DePue, B.E.; Haas, H.E.; Hofmann, S.G.; Kangas, M.; Kensinger, E.; Lowry, C.A.; Marusak, H.A.; et al. Current understanding of fear learning and memory in humans and animal models and the value of a linguistic approach for analyzing fear learning and memory in humans. Neurosci. Biobehav. Rev. 2019, 105, 136–177. [Google Scholar] [CrossRef] [PubMed]
  43. Rasmusson, A.M.; Marx, C.E.; Pineles, S.L.; Locci, A.; Scioli-Salter, E.R.; Nillni, Y.I.; Liang, J.; Pinna, G. Neuroactive steroids and PTSD treatment. Neurosci. Lett. 2017, 649, 156–163. [Google Scholar] [CrossRef] [PubMed]
  44. Jiang, B.; Huang, C.; Zhu, Q.; Tong, L.-J.; Zhang, W. WY14643 produces anti-depressant-like effects in mice via the BDNF signaling pathway. Psychopharmacol. 2014, 232, 1629–1642. [Google Scholar] [CrossRef] [PubMed]
  45. Jiang, B.; Wang, Y.-J.; Wang, H.; Song, L.; Huang, C.; Zhu, Q.; Wu, F.; Zhang, W. Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br. J. Pharmacol. 2016, 174, 177–194. [Google Scholar] [CrossRef]
  46. Lin, P.-Y.; Chang, A.Y.; Lin, T.-K. Simvastatin treatment exerts antidepressant-like effect in rats exposed to chronic mild stress. Pharmacol. Biochem. Behav. 2014, 124, 174–179. [Google Scholar] [CrossRef]
  47. Zhao, Q.; Wu, X.; Yan, S.; Xie, X.; Fan, Y.; Zhang, J.; Peng, C.; You, Z. The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes. J. Neuroinflammation 2016, 13, 259. [Google Scholar] [CrossRef]
  48. Pibiri, F.; Nelson, M.; Guidotti, A.; Costa, E.; Pinna, G. Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: A model relevant for posttraumatic stress disorder. Proc. Natl. Acad. Sci. USA 2008, 105, 5567–5572. [Google Scholar] [CrossRef]
  49. Pinna, G.; Agís-Balboa, R.C.; Pibiri, F.; Nelson, M.; Guidotti, A.; Costa, E. Neurosteroid Biosynthesis Regulates Sexually Dimorphic Fear and Aggressive Behavior in Mice. Neurochem. Res. 2008, 33, 1990–2007. [Google Scholar] [CrossRef]
  50. Sullivan, C.R.; Mielnik, C.A.; O’Donovan, S.; Funk, A.J.; Bentea, E.; DePasquale, E.A.; Alganem, K.; Wen, Z.; Haroutunian, V.; Katsel, P.; et al. Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments. Mol. Neurobiol. 2018, 56, 4492–4517. [Google Scholar] [CrossRef]
  51. Choi, J.; Lee, S.; Won, J.; Jin, Y.; Hong, Y.; Hur, T.-Y.; Kim, J.-H.; Lee, S.-R.; Hong, Y. Pathophysiological and neurobehavioral characteristics of a propionic acid-mediated autism-like rat model. PLoS ONE 2018, 13, e0192925. [Google Scholar] [CrossRef] [PubMed]
  52. Mirza, R.; Sharma, B. Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. Brain Res. Bull. 2019, 147, 36–46. [Google Scholar] [CrossRef] [PubMed]
  53. Cristiano, C.; Pirozzi, C.; Coretti, L.; Cavaliere, G.; Lama, A.; Russo, R.; Lembo, F.; Mollica, M.P.; Esposito, E.; Calignano, A.; et al. Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms. Brain Behav. Immun. 2018, 74, 166–175. [Google Scholar] [CrossRef] [PubMed]
  54. Ahmad, S.F.; Nadeem, A.; Ansari, M.A.; Bakheet, S.A.; Alshammari, M.A.; Attia, S.M. The PPARδ agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model. Neurochem. Int. 2018, 120, 251–261. [Google Scholar] [CrossRef]
  55. Quinn, L.P.; Crook, B.; E Hows, M.; Vidgeon-Hart, M.; Chapman, H.; Upton, N.; Medhurst, A.D.; Virley, D.J. The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 2008, 154, 226–233. [Google Scholar] [CrossRef]
  56. Dehmer, T.; Heneka, M.T.; Sastre, M.; Dichgans, J.; Schulz, J.B. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with IκBα induction and block of NFκB and iNOS activation. J. Neurochem. 2004, 88, 494–501. [Google Scholar] [CrossRef]
  57. Schintu, N.; Frau, L.; Ibba, M.; Caboni, P.; Garau, A.; Carboni, E.; Carta, A. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur. J. Neurosci. 2009, 29, 954–963. [Google Scholar] [CrossRef]
  58. Cuzzocrea, S. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. Vasc. Pharmacol. 2004, 41, 187–195. [Google Scholar] [CrossRef]
  59. Devchand, P.R.; Keller, H.; Peters, J.M.; Vazquez, M.; Gonzalez, F.J.; Wahli, W. The PPARα–leukotriene B4 pathway to inflammation control. Nature. 1996, 384, 39–43. [Google Scholar] [CrossRef]
  60. Paterniti, I.; Impellizzeri, D.; Crupi, R.; Morabito, R.; Campolo, M.; Esposito, E.; Cuzzocrea, S. Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J. Neuroinflammation 2013, 10, 20. [Google Scholar] [CrossRef]
  61. Citraro, R.; Russo, E.; Scicchitano, F.; Van Rijn, C.M.; Cosco, D.; Avagliano, C.; Russo, R.; D’Agostino, G.; Petrosino, S.; Guida, F.; et al. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. Neuropharmacol. 2013, 69, 115–126. [Google Scholar] [CrossRef] [PubMed]
  62. Galimberti, D.; Scarpini, E. Pioglitazone for the treatment of Alzheimer’s disease. Expert Opin. Investig. Drugs 2016, 26, 97–101. [Google Scholar] [CrossRef] [PubMed]
  63. Reich, D.; Gallucci, G.; Tong, M.; De La Monte, S.M. Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease. J. Park. Dis. Alzheimer’s Dis. 2018, 5, 01–08. [Google Scholar]
  64. Niino, M.; Iwabuchi, K.; Kikuchi, S.; Ato, M.; Morohashi, T.; Ogata, A.; Tashiro, K.; Onoé, K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ. J. Neuroimmunol. 2001, 116, 40–48. [Google Scholar] [CrossRef]
  65. Roohafza, H.; Shokouh, P.; Sadeghi, M.; Alikhassy, Z.; Sarrafzadegan, N. A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial. Int. Sch. Res. Not. 2014, 2014, 1–9. [Google Scholar] [CrossRef] [PubMed]
  66. Kemp, D.E.; Schinagle, M.; Gao, K.; Conroy, C.; Ganocy, S.J.; Ismail-Beigi, F.; Calabrese, J.R.; Gao, K. PPAR-γ agonism as a modulator of mood: Proof-of-concept for pioglitazone in bipolar depression. CNS Drugs 2014, 28, 571–581. [Google Scholar] [CrossRef] [PubMed]
  67. Aftab, A.; Kemp, D.E.; Ganocy, S.J.; Schinagle, M.; Conroy, C.; Brownrigg, B.; D’Arcangelo, N.; Goto, T.; Woods, N.; Serrano, M.B.; et al. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J. Affect. Disord. 2019, 245, 957–964. [Google Scholar] [CrossRef]
  68. Lin, K.W.; Wroolie, T.E.; Robakis, T.; Rasgon, N.L. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Res. 2015, 230, 846–852. [Google Scholar] [CrossRef]
  69. Ghazizadeh-Hashemi, M.; Ghajar, A.; Shalbafan, M.-R.; Ghazizadeh-Hashemi, F.; Afarideh, M.; Malekpour, F.; Ghaleiha, A.; Ardebili, M.E.; Akhondzadeh, S. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J. Affect. Disord. 2018, 232, 127–133. [Google Scholar] [CrossRef]
  70. Capano, L.; Dupuis, A.; Brian, J.; Mankad, D.; Genore, L.; Adams, R.H.; Smile, S.; Lui, T.; Odrobina, D.; Foster, J.A.; et al. A pilot dose finding study of pioglitazone in autistic children. Mol. Autism 2018, 9, 59. [Google Scholar] [CrossRef]
  71. Geldmacher, D.S.; Fritsch, T.; McClendon, M.J.; Landreth, G. A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease. Arch. Neurol. 2011, 68, 45–50. [Google Scholar] [CrossRef] [PubMed]
  72. Kaiser, C.C.; Shukla, D.K.; Stebbins, G.T.; Skias, D.D.; Jeffery, D.R.; Stefoski, D.; Katsamakis, G.; Feinstein, U.L. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J. Neuroimmunol. 2009, 211, 124–130. [Google Scholar] [CrossRef] [PubMed]
  73. Costa, A.; Cristiano, C.; Cassano, T.; Gallelli, C.A.; Gaetani, S.; Ghelardini, C.; Blandina, P.; Calignano, A.; Passani, M.B.; Provensi, G. Histamine-deficient mice do not respond to the antidepressant-like effects of oleoylethanolamide. Neuropharmacology 2018, 135, 234–241. [Google Scholar] [CrossRef] [PubMed]
  74. Ferreira, M.F.; Castanheira, L.; Sebastiao, A.M.; Telles-Correia, D. Depression Assessment in Clinical Trials and Pre-clinical Tests: A Critical Review. Curr. Top. Med. Chem. 2018, 18, 1677–1703. [Google Scholar] [CrossRef]
  75. Lu, B.; Nagappan, G.; Lu, Y. BDNF and Synaptic Plasticity, Cognitive Function, and Dysfunction. Neuropharmacol. Alcohol 2014, 220, 223–250. [Google Scholar]
  76. Kowiański, P.; Lietzau, G.; Czuba, E.; Waśkow, M.; Steliga, A.; Moryś, J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell. Mol. Neurobiol. 2017, 38, 579–593. [Google Scholar] [CrossRef]
  77. Björkholm, C.; Monteggia, L. BDNF - a key transducer of antidepressant effects. Neuropharmacology 2015, 102, 72–79. [Google Scholar] [CrossRef]
  78. Zaletel, I.; Filipovic, D.; Puškaš, N. Hippocampal BDNF in physiological conditions and social isolation. Rev. Neurosci. 2017, 28, 675–692. [Google Scholar] [CrossRef]
  79. Lee, B.-H.; Kim, Y.-K. The Roles of BDNF in the Pathophysiology of Major Depression and in Antidepressant Treatment. Psychiatry Investig. 2010, 7, 231–235. [Google Scholar] [CrossRef]
  80. Mondal, A.C.; Fatima, M. Direct and indirect evidences of BDNF and NGF as key modulators in depression: Role of antidepressants treatment. Int. J. Neurosci. 2018, 129, 283–296. [Google Scholar] [CrossRef]
  81. Erickson, K.I.; Miller, D.L.; Roecklein, K.A. The aging hippocampus: Interactions between exercise, depression, and BDNF. Neuroscientist 2012, 18, 82–97. [Google Scholar] [CrossRef] [PubMed]
  82. Caviedes, A.; Lafourcade, C.; Soto, C.; Wyneken, U.; Caviedes, C.L.A. BDNF/NF-κB Signaling in the Neurobiology of Depression. Curr. Pharm. Des. 2017, 23, 3154–3163. [Google Scholar] [CrossRef] [PubMed]
  83. Castrén, E.; Rantamäki, T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70, 289–297. [Google Scholar] [CrossRef] [PubMed]
  84. Keating, G.M.; Croom, K.F. Fenofibrate. Drugs 2007, 67, 121–153. [Google Scholar] [CrossRef] [PubMed]
  85. Roy, A.; Jana, M.; Corbett, G.; Ramaswamy, S.; Kordower, J.H.; Gonzalez, F.J.; Pahan, K. Regulation of Cyclic AMP Response Element Binding and Hippocampal Plasticity-Related Genes by Peroxisome Proliferator-Activated Receptor α. Cell Rep. 2013, 4, 724–737. [Google Scholar] [CrossRef] [PubMed]
  86. Roy, A.; Kundu, M.; Jana, M.; Mishra, R.K.; Yung, Y.; Luan, C.-H.; Gonzalez, F.J.; Pahan, K. Identification and characterization of PPARα ligands in the hippocampus. Nat. Methods 2016, 12, 1075–1083. [Google Scholar] [CrossRef]
  87. Choi, M.-J.; Lee, E.-J.; Park, J.-S.; Kim, S.-N.; Park, E.-M.; Kim, H.-S. Anti-inflammatory mechanism of galangin in lipopolysaccharide-stimulated microglia: Critical role of PPAR-γ signaling pathway. Biochem. Pharmacol. 2017, 144, 120–131. [Google Scholar] [CrossRef]
  88. Roy, A.; Jana, M.; Kundu, M.; Corbett, G.; Rangaswamy, S.B.; Mishra, R.K.; Luan, C.-H.; Gonzalez, F.J.; Pahan, K. HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. Cell Metab. 2015, 22, 253–265. [Google Scholar] [CrossRef]
  89. Song, L.; Wang, H.; Wang, Y.-J.; Wang, J.-L.; Zhu, Q.; Wu, F.; Zhang, W.; Jiang, B. Hippocampal PPARα is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice. Br. J. Pharmacol. 2018, 175, 2968–2987. [Google Scholar] [CrossRef]
  90. Raso, G.M.; Russo, R.; Calignano, A.; Meli, R. Palmitoylethanolamide in CNS health and disease. Pharmacol. Res. 2014, 86, 32–41. [Google Scholar] [CrossRef]
  91. Petrosino, S.; Di Marzo, V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br. J. Pharmacol. 2016, 174, 1349–1365. [Google Scholar] [CrossRef] [PubMed]
  92. Biernacki, M.; Skrzydlewska, E. Metabolism of endocannabinoids. Postępy Higieny i Medycyny Doświadczalnej 2016, 70, 830–843. [Google Scholar] [CrossRef] [PubMed]
  93. Godlewski, G.; Offertáler, L.; Wagner, J.A.; Kunos, G. Receptors for acylethanolamides—GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009, 89, 105–111. [Google Scholar] [CrossRef] [PubMed]
  94. Rigano, D.; Sirignano, C.; Taglialatela-Scafati, O. The potential of natural products for targeting PPAR α. Acta Pharm. Sin. B 2017, 7, 427–438. [Google Scholar] [CrossRef] [PubMed]
  95. Uzunova, V.; Sheline, Y.; Davis, J.M.; Rasmusson, A.; Uzunov, D.P.; Costa, E.; Guidotti, A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA 1998, 95, 3239–3244. [Google Scholar] [CrossRef] [PubMed]
  96. Rasmusson, A.M.; Pinna, G.; Paliwal, P.; Weisman, D.; Gottschalk, C.; Charney, D.; Krystal, J.; Guidotti, A. Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder. Boil. Psychiatry 2006, 60, 704–713. [Google Scholar] [CrossRef]
  97. Pineles, S.L.; Nillni, Y.; Pinna, G.; Irvine, J.; Webb, A.; Hall, K.A.; Hauger, R.; Miller, M.; Resick, P.A.; Orr, S.; et al. PTSD in women is associated with a block in conversion of progesterone to the GABAergic neurosteroids allopregnanolone and pregnanolone measured in plasma. Psychoneuroendocrinology 2018, 93, 133–141. [Google Scholar] [CrossRef]
  98. Agis-Balboa, R.C.; Guidotti, A.; Pinna, G. 5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann’s area 9 (BA9) of depressed patients. Psychopharmacology (Berl) 2014, 231, 3569–3580. [Google Scholar] [CrossRef]
  99. Romeo, E.; Ströhle, A.; Spalletta, G.; Di Michele, F.; Hermann, B.; Holsboer, F.; Pasini, A.; Rupprecht, R. Effects of Antidepressant Treatment on Neuroactive Steroids in Major Depression. Am. J. Psychiatry 1998, 155, 910–913. [Google Scholar] [CrossRef]
  100. Wilker, S.; Pfeiffer, A.; Elbert, T.; Ovuga, E.; Karabatsiakis, A.; Krumbholz, A.; Thieme, D.; Schelling, G.; Kolassa, I.-T. Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 2016, 67, 198–206. [Google Scholar] [CrossRef]
  101. Aspesi, D.; Pinna, G. Could a blood test for PTSD and depression be on the horizon? Expert Rev. Proteom. 2018, 15, 1–24. [Google Scholar] [CrossRef] [PubMed]
  102. Rasmusson, A.M.; King, M.W.; Valovski, I.; Gregor, K.; Scioli-Salter, E.; Pineles, S.L.; Hamouda, M.; Nillni, Y.I.; Anderson, G.M.; Pinna, G. Relationships between cerebrospinal fluid GABAergic neurosteroid levels and symptom severity in men with PTSD. Psychoneuroendocrinology 2019, 102, 95–104. [Google Scholar] [CrossRef] [PubMed]
  103. Agís-Balboa, R.C.; Pinna, G.; Pibiri, F.; Kadriu, B.; Costa, E.; Guidotti, A. Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. Proc. Natl. Acad. Sci. USA 2007, 104, 18736–18741. [Google Scholar] [CrossRef] [PubMed]
  104. Kemp, D.E.; Ismail-Beigi, F.; Calabrese, J.R. Antidepressant response associated with pioglitazone: Support for an overlapping pathophysiology between major depression and metabolic syndrome. Am. J. Psychiatry 2009, 166, 619. [Google Scholar] [CrossRef] [PubMed]
  105. Sepanjnia, K.; Modabbernia, A.; Ashrafi, M.; Modabbernia, M.-J.; Akhondzadeh, S. Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial. Neuropsychopharmacol. 2012, 37, 2093–2100. [Google Scholar] [CrossRef] [PubMed]
  106. Guo, M.; Li, C.; Lei, Y.; Xu, S.; Zhao, D.; Lu, X.-Y. Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors. Mol. Psychiatry 2016, 22, 1056–1068. [Google Scholar] [CrossRef]
  107. Müller, N. Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. Schizophr. Bull. 2018, 44, 973–982. [Google Scholar] [CrossRef]
  108. Martínez-Gras, I.; Perez-Nievas, B.G.; García-Bueno, B.; Madrigal, J.; Andrés-Esteban, E.; Rodríguez-Jiménez, R.; Hoenicka, J.; Palomo, T.; Rubio, G.; Leza, J.C. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr. Res. 2011, 128, 15–22. [Google Scholar] [CrossRef]
  109. Chase, K.; Rosen, C.; Gin, H.; Bjorkquist, O.; Feiner, B.; Marvin, R.; Conrin, S.; Sharma, R.P. Metabolic and inflammatory genes in schizophrenia. Psychiatry Res. 2014, 225, 208–211. [Google Scholar] [CrossRef]
  110. O’Connor, A.M.; Burton, T.J.; Leamey, C.A.; Sawatari, A. The Use of the Puzzle Box as a Means of Assessing the Efficacy of Environmental Enrichment. J. Vis. Exp. 2014, 94, 52225. [Google Scholar] [CrossRef]
  111. Bougarne, N.; Weyers, B.; Desmet, S.J.; Deckers, J.; Ray, D.W.; Staels, B.; De Bosscher, K. Molecular Actions of PPARα in Lipid Metabolism and Inflammation. Endocr. Rev. 2018, 39, 760–802. [Google Scholar] [CrossRef] [PubMed]
  112. De Felice, M.; Melis, M.; Aroni, S.; Muntoni, A.L.; Fanni, S.; Frau, R.; Devoto, P.; Pistis, M. The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia. CNS Neurosci. Ther. 2018, 25, 549–561. [Google Scholar] [CrossRef] [PubMed]
  113. Liu, H.; Talalay, P.; Fahey, J. Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD). CNS Neurol. Disord. - Drug Targets 2016, 15, 1. [Google Scholar] [CrossRef] [PubMed]
  114. Mirza, R.; Sharma, B. Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-γ agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats. Int. J. Dev. Neurosci. 2019, 76, 6–16. [Google Scholar] [CrossRef] [PubMed]
  115. Mirza, R.; Sharma, B. A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. Chem. Interactions 2019, 311, 108758. [Google Scholar] [CrossRef] [PubMed]
  116. Bambini-Junior, V.; Zanatta, G.; Nunes, G.D.-F.; De Melo, G.M.; Michels, M.; Fontes-Dutra, M.; Freire, V.N.; Riesgo, R.; Gottfried, C. Resveratrol prevents social deficits in animal model of autism induced by valproic acid. Neurosci. Lett. 2014, 583, 176–181. [Google Scholar] [CrossRef]
  117. Barone, R.; Rizzo, R.; Tabbì, G.; Malaguarnera, M.; Frye, R.E.; Bastin, J. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder. Int. J. Mol. Sci. 2019, 20, 1878. [Google Scholar] [CrossRef]
  118. D’Agostino, G.; Cristiano, C.; Lyons, D.; Citraro, R.; Russo, E.; Avagliano, C.; Russo, R.; Raso, G.M.; Meli, R.; De Sarro, G.; et al. Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice. Mol. Metab. 2015, 4, 528–536. [Google Scholar] [CrossRef]
  119. Magadum, A.; Engel, F.B. PPARβ/δ: Linking Metabolism to Regeneration. Int. J. Mol. Sci. 2018, 19, 2013. [Google Scholar] [CrossRef]
  120. Pinna, G. Biomarkers for PTSD at the Interface of the Endocannabinoid and Neurosteroid Axis. Front. Mol. Neurosci. 2018, 12, 482. [Google Scholar] [CrossRef]
  121. Bai, S.; Guo, W.; Feng, Y.; Deng, H.; Li, G.; Nie, H.; Guo, G.; Yu, H.; Ma, Y.; Wang, J.; et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: A systematic review and meta-analysis of randomised controlled trials. J. Neurol. Neurosurg. Psychiatry 2019, 91, 21–32. [Google Scholar] [CrossRef] [PubMed]
  122. De Gregorio, D.; Manchia, M.; Carpiniello, B.; Valtorta, F.; Nobile, M.; Gobbi, G.; Comai, S. Role of palmitoylethanolamide (PEA) in depression: Translational evidence. J. Affect. Disord. 2019, 255, 195–200. [Google Scholar] [CrossRef] [PubMed]
  123. Agarwal, S.; Yadav, A.; Chaturvedi, R.K. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem. Biophys. Res. Commun. 2017, 483, 1166–1177. [Google Scholar] [CrossRef] [PubMed]
  124. D’Orio, B.; Fracassi, A.; Ceru, M.P.; Moreno, S. Targeting PPARalpha in Alzheimer’s Disease. Curr. Alzheimer Res. 2018, 15, 345–354. [Google Scholar] [CrossRef]
  125. Vallée, A.; LeCarpentier, Y. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma. Front. Mol. Neurosci. 2016, 10, 516. [Google Scholar] [CrossRef]
  126. Papadopoulos, P.; Rosa-Neto, P.; Rochford, J.; Hamel, E. Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer’s Disease with Combined Amyloid-β and Cerebrovascular Pathology. PLoS ONE 2013, 8, e68612. [Google Scholar] [CrossRef]
  127. Beggiato, S.; Tomasini, M.C.; Ferraro, L. Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease. Front. Pharmacol. 2019, 10, 821. [Google Scholar] [CrossRef]
  128. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.N. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim. Biophys. Sin. (Shanghai) 2017, 49, 853–866. [Google Scholar] [CrossRef]
  129. Szalardy, L.; Zadori, D.; Tánczos, E.; Simu, M.; Bencsik, K.; Vécsei, L.; Klivényi, P. Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. Neurosci. Lett. 2013, 554, 131–134. [Google Scholar] [CrossRef]
  130. Szalardy, L.; Zadori, D.; Bencsik, K.; Vecsei, L.; Klivényi, P. Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis. Neurosci. Lett. 2017, 651, 128–133. [Google Scholar] [CrossRef]
  131. Ferret-Sena, V.; Capela, C.; Sena, A. Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis. Int. J. Mol. Sci. 2018, 19, 1639. [Google Scholar] [CrossRef] [PubMed]
  132. Minter, M.R.; Taylor, J.; Crack, P. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J. Neurochem. 2015, 136, 457–474. [Google Scholar]
  133. Klotz, L.; Schmidt, S.; Heun, R.; Klockgether, T.; Kölsch, H. Association of the PPARγ gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci. Lett. 2009, 449, 81–83. [Google Scholar] [CrossRef] [PubMed]
  134. Corona, J.C.; Gimenez-Cassina, A.; Lim, F.; Díaz-Nido, J. Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson’s disease. J. Neurosci. Res. 2010, 88, 1943–1950. [Google Scholar] [CrossRef] [PubMed]
  135. Lee, Y.; Cho, J.-H.; Lee, S.; Lee, W.; Chang, S.-C.; Chung, H.Y.; Moon, H.R.; Lee, J. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson’s disease model. Brain Res. 2019, 1704, 47–58. [Google Scholar] [CrossRef]
  136. Lecca, D.; Janda, E.; Mulas, G.; Diana, A.; Martino, C.; Angius, F.; Spolitu, S.; Casu, M.A.; Simbula, G.; Boi, L.; et al. Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson’s disease models. Br. J. Pharmacol. 2018, 175, 3298–3314. [Google Scholar] [CrossRef]
  137. Islam, M. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol. Res. 2016, 39, 73–82. [Google Scholar] [CrossRef]
  138. Mudo, G.; Mäkelä, J.; Di Liberto, V.; Tselykh, T.V.; Olivieri, M.; Piepponen, P.; Eriksson, O.; Mälkiä, A.; Bonomo, A.; Kairisalo, M.; et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell. Mol. Life Sci. 2011, 69, 1153–1165. [Google Scholar] [CrossRef]
  139. Beghi, E.; Giussani, G.; Sander, J. The natural history and prognosis of epilepsy. Epileptic Disord 2015, 17, 243–253. [Google Scholar] [CrossRef]
  140. Puligheddu, M.; Melis, M.; Pillolla, G.; Milioli, G.; Parrino, L.; Terzano, G.M.; Aroni, S.; Sagheddu, C.; Marrosu, F.; Pistis, M.; et al. Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy. Epilepsia 2017, 58, 1762–1770. [Google Scholar] [CrossRef]
  141. Coenen, A.M.L.; Van Luijtelaar, E.L.J.M. Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats. Behav. Genet. 2003, 33, 635–655. [Google Scholar] [CrossRef]
  142. Matrisciano, F.; Pinna, G. Functional food and nutrition for the management of autism spectrum disorders and schizophrenia. In Functional Foods and Mental Health, 1st ed.; Independently published; 2019; pp. 307–330, ISBN-13: 978-1704411873; ISBN-10: 1704411874. [Google Scholar]
Molecules 25 01062 g001
Figure 1. Schematic representation of PPAR-α and PPAR-γ signal cascade following their activation by endogenous or synthetic ligands. PPAR-α endogenous and synthetic agonists, including PEA and the fibrates, activate PPAR-α that dimerizes with the retinoid X-receptor (RXR) and activates the calcium influx through transcriptional regulation of cyclic AMP response element-binding protein (CREB), which in turn promotes hippocampal brain derived neurotropic factor (BDNF) signaling cascade. PPAR-α activation also upregulates both the steroidogenic acute regulatory protein (StAR), which forms a complex with cholesterol and translocator protein (TSPO) allowing the entry of cholesterol into the inner mitochondria membrane where cholesterol is transformed into pregnenolone (PE), the precursors of all neurosteroids, through the cholesterol side-chain cleavage enzyme (P450scc). PE, which is translocated to cortical and hippocampus glutamatergic pyramidal neurons is then converted in allopregnanolone. Allopregnanolone enhances γ-aminobutyric acid action at GABAA receptors [9,10] and improves emotional behavior. Allopregnanolone may also exert an important anti-inflammatory action by binding at α2-containing GABAA receptor subtypes located in glial cells, through inhibition of toll-like 4 receptor/NF-κB pathway [11]. PPAR-γ agonists potentiate the PPAR-γ-induced inhibitory action on NF-κB, which is responsible for microglial activated status, neuroinflammation and neurodegeneration. Moreover, NF-κB inhibits the hippocampal BDNF signaling cascade [12,13]. Thus, PPAR-γ agonists exert an anti-inflammatory effect, by decreasing pro-inflammatory cytokines IL-6, IL-1β, TNF-α, as well as the JAK-2/STAT3 pathway, which is involved in immunity processes. Additionally, activation of PPAR-γ plays a neuroprotective action by decreasing the inhibition on BDNF signaling pathway.
Figure 1. Schematic representation of PPAR-α and PPAR-γ signal cascade following their activation by endogenous or synthetic ligands. PPAR-α endogenous and synthetic agonists, including PEA and the fibrates, activate PPAR-α that dimerizes with the retinoid X-receptor (RXR) and activates the calcium influx through transcriptional regulation of cyclic AMP response element-binding protein (CREB), which in turn promotes hippocampal brain derived neurotropic factor (BDNF) signaling cascade. PPAR-α activation also upregulates both the steroidogenic acute regulatory protein (StAR), which forms a complex with cholesterol and translocator protein (TSPO) allowing the entry of cholesterol into the inner mitochondria membrane where cholesterol is transformed into pregnenolone (PE), the precursors of all neurosteroids, through the cholesterol side-chain cleavage enzyme (P450scc). PE, which is translocated to cortical and hippocampus glutamatergic pyramidal neurons is then converted in allopregnanolone. Allopregnanolone enhances γ-aminobutyric acid action at GABAA receptors [9,10] and improves emotional behavior. Allopregnanolone may also exert an important anti-inflammatory action by binding at α2-containing GABAA receptor subtypes located in glial cells, through inhibition of toll-like 4 receptor/NF-κB pathway [11]. PPAR-γ agonists potentiate the PPAR-γ-induced inhibitory action on NF-κB, which is responsible for microglial activated status, neuroinflammation and neurodegeneration. Moreover, NF-κB inhibits the hippocampal BDNF signaling cascade [12,13]. Thus, PPAR-γ agonists exert an anti-inflammatory effect, by decreasing pro-inflammatory cytokines IL-6, IL-1β, TNF-α, as well as the JAK-2/STAT3 pathway, which is involved in immunity processes. Additionally, activation of PPAR-γ plays a neuroprotective action by decreasing the inhibition on BDNF signaling pathway.
Molecules 25 01062 g001
Molecules 25 01062 g002
Figure 2. List of endogenous and synthetic PPAR- α, PPAR-γ and dual PPAR- α/γ ligands.
Figure 2. List of endogenous and synthetic PPAR- α, PPAR-γ and dual PPAR- α/γ ligands.
Molecules 25 01062 g002
Table 1. Studies of peroxisome proliferator-activated receptor (PPAR) ligands in models of neuropsychiatric disorders.
Table 1. Studies of peroxisome proliferator-activated receptor (PPAR) ligands in models of neuropsychiatric disorders.
Preclinical Studies
Models of mood disorders
DiseaseModelAgonistMolecular TargetEffectReferences
DepressionGW-9662 treatmentRosiglitazonePPAR-γAntidepressant effect; reduce the immobility time in the forced swim test[18]
Chronic social defeat stress WY14643PPAR-αImprove depressive-like behavior in the tail suspension test and forced swim test[44]
Chronic social defeat stressFenofibratePPAR-αAntidepressant-like effects [45]
CMS-exposed ratsSimvastatinPPAR-αReverse the depression-like behaviors promoting BDNF signaling pathway [46]
CMS-exposed micePioglitazonePPAR-γDecrease microglial activated status (Iba1+) and pro-inflammatory cytokines[47]
PTSDSocially isolated miceFenofibrate PEAPPAR-αIncrease brain levels of allopregnanolone; Improve anxiety-like behavior; facilitate contextual fear extinction and fear extinction retention[10], [48], [49]
Models of neurodevelopmental disorders
SchizophreniaGluN1 knockdownPioglitazonePPAR-γImprove long-term memory and help restoring cognitive endophenotypes[50]
ASDPropionic acid autism-like rat Pioglitazone (from postnatal day 24)PPAR-γMitigate the ASD-like behavior and reduce oxidative stress and inflammation[51]
VPA-autism like Wistar ratFenofibratePPAR-αReduce oxidative stress and inflammation in several brain regions[52]
BTBRPEAPPAR-αRevert the altered phenotype and improve ASD-like behavior[53]
BTBRGW0742PPAR-β/δ Improve repetitive behaviors and lowers thermal sensitivity responses; decrease pro-inflammatory cytokines [54]
Model of neurological disorders
PDMPTP PioglitazonePPAR-γProtect against neurotoxicity; decrease microglial activation and iNOS-positive cells[55]
MPTP RosiglitazonePPAR-γProtect from dopaminergic neurons loss; prevents olfactory and motor alteration[56], [57]
MPTP MHY908PPAR-α/γ dual agonistNeuroprotective effects; reduce microglial activation and neuroinflammation[58]
MPTP MDG548PPAR-γMediate neuroprotection in microglia; promote anti-inflammatory cytokines[59]
MPTPPioglitazonePPAR-γDecrease microglial activation and iNOS-positive cells [60]
EpilepsyWAG/Rij ratsPEAPPAR-αAttenuate seizures [61]
ADGenetically modified AD mouse PioglitazonePPAR-γImprove memory and learning deficits; prevent neurodegeneration[62]
Streptozotocin rat L165, 041 and F-L-LeuL165, 041 and F-L-Leu, simultaneouslyPPAR-β/δ and PPAR-γ, Improve myelin and neuronal maturation, mitochondrial proliferation and function; decrease neuroinflammation[63]
MSEAETroglitazonePPAR-γAttenuate inflammation[64]
Table 2. Effects of PPAR ligands in neuropsychiatric disorders.
Table 2. Effects of PPAR ligands in neuropsychiatric disorders.
Clinical Studies
Mood disorders
MDDClinical TrialRosiglitazonePPAR-γImprove symptoms; normalize pro-inflammatory cytokines[16]
Double-blind, randomized clinical trial; 24-week.PioglitazonePPAR-γImprove anxiety and depression [65]
Bipolar depression Pioglitazone (15–30 mg/day for 8 weeks)PPAR-γImprove depressive symptoms [66]
Double-blind, randomized, placebo-controlled trialPioglitazone (15–45 mg/day for 8 weeks) PPAR-γFail to improve bipolar depression symptoms [67]
Double-blind, randomized, placebo-controlled trialPioglitazone (30 mg/day for 12 weeks)PPAR-γDifferential improvement according to metabolic and depressive status [68]
Double-blind, randomized, placebo-controlled trialPalmitoylethanolamide (PEA)PPAR-αImprove depressive symptoms[69]
Neurodevelopmental disorders
ASD16-week prospective study of autistic childrenPioglitazonePPAR-γImprove repetitive and externalizing behaviors, social withdrawal[70]
Neurological disorders
ADDouble-blind, randomized, placebo-controlled trialPioglitazone (45 mg/day for 18 months)PPAR-γNo significant effect[71]
MSClinical trial, 12 month-treatmentPioglitazonePPAR-γNo improvement in clinical symptoms; decrease grey matter atrophy[72]

Share and Cite

MDPI and ACS Style

Tufano, M.; Pinna, G. Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders? Molecules 2020, 25, 1062. https://doi.org/10.3390/molecules25051062

AMA Style

Tufano M, Pinna G. Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders? Molecules. 2020; 25(5):1062. https://doi.org/10.3390/molecules25051062

Chicago/Turabian Style

Tufano, Michele, and Graziano Pinna. 2020. "Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?" Molecules 25, no. 5: 1062. https://doi.org/10.3390/molecules25051062

APA Style

Tufano, M., & Pinna, G. (2020). Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders? Molecules, 25(5), 1062. https://doi.org/10.3390/molecules25051062

Article Metrics

Back to TopTop